Market icon
Finanzen·Aktien

Wird Johnson & Johnson (JNJ) das Quartalsergebnis übertreffen?

Market icon
Finanzen·Aktien

Wird Johnson & Johnson (JNJ) das Quartalsergebnis übertreffen?

Ja

87% Chance
Polymarket
NEU

Ja

87% Chance
Polymarket
NEU
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Trader consensus on Polymarket prices an 86.5% implied probability on Johnson & Johnson (JNJ) beating Q1 2026 earnings estimates, driven by the company's track record of consistent beats—including Q4 2025 adjusted EPS of $2.46 surpassing Zacks consensus by 1.2% alongside a 9.1% revenue surge to $24.6 billion—and upbeat full-year 2026 guidance of $11.43–$11.63 adjusted EPS, exceeding analyst forecasts of $11.45. Recent catalysts include a $500 million R&D co-funding deal with Royalty Pharma for immunology assets and a quarterly dividend hike to $1.24 per share, reinforcing defensive growth in pharmaceuticals amid sector tailwinds. Consensus EPS for April 14 release stands at $2.60, with Zacks Rank #2 (Buy) signaling potential positive Earnings Surprise Prediction; resolution hinges on Innovative Medicine segment performance.

As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.

If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Volumen
$524
Enddatum
14. Apr. 2026
Markt eröffnet
Mar 30, 2026, 7:54 PM ET

Abwicklungsquelle

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Trader consensus on Polymarket prices an 86.5% implied probability on Johnson & Johnson (JNJ) beating Q1 2026 earnings estimates, driven by the company's track record of consistent beats—including Q4 2025 adjusted EPS of $2.46 surpassing Zacks consensus by 1.2% alongside a 9.1% revenue surge to $24.6 billion—and upbeat full-year 2026 guidance of $11.43–$11.63 adjusted EPS, exceeding analyst forecasts of $11.45. Recent catalysts include a $500 million R&D co-funding deal with Royalty Pharma for immunology assets and a quarterly dividend hike to $1.24 per share, reinforcing defensive growth in pharmaceuticals amid sector tailwinds. Consensus EPS for April 14 release stands at $2.60, with Zacks Rank #2 (Buy) signaling potential positive Earnings Surprise Prediction; resolution hinges on Innovative Medicine segment performance.

As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.

If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Volumen
$524
Enddatum
14. Apr. 2026
Markt eröffnet
Mar 30, 2026, 7:54 PM ET

Abwicklungsquelle

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, Johnson & Johnson is estimated to release earnings on April 14, 2026. The Street consensus estimate for Johnson & Johnson’s non-GAAP EPS for the relevant quarter is $2.68 as of market creation. This market will resolve to "Yes" if Johnson & Johnson reports non-GAAP EPS greater than $2.68 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Johnson & Johnson releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Vorsicht bei externen Links.

Häufig gestellte Fragen

„Wird Johnson & Johnson (JNJ) das Quartalsergebnis übertreffen?" ist ein Prognosemarkt auf Polymarket mit 2 möglichen Ergebnissen, bei dem Händler Anteile auf Basis ihrer Einschätzung kaufen und verkaufen. Das aktuell führende Ergebnis ist „Wird Johnson & Johnson (JNJ) die Quartalsergebnisse übertreffen?" mit 87%. Die Preise spiegeln Echtzeit-Wahrscheinlichkeiten der Community wider. Ein Anteilspreis von 87¢ bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 87% zuweist. Diese Quoten ändern sich laufend, wenn Händler auf neue Entwicklungen reagieren. Anteile am richtigen Ergebnis können bei Marktauflösung für jeweils $1 eingelöst werden.

„Wird Johnson & Johnson (JNJ) das Quartalsergebnis übertreffen?" ist ein neu erstellter Markt auf Polymarket, gestartet am Mar 30, 2026. Als früher Markt haben Sie die Gelegenheit, zu den ersten Händlern zu gehören, die die Quoten setzen und die ersten Preissignale des Marktes etablieren. Sie können diese Seite auch als Lesezeichen speichern, um Volumen und Handelsaktivität zu verfolgen, während der Markt an Fahrt gewinnt.

Um auf „Wird Johnson & Johnson (JNJ) das Quartalsergebnis übertreffen?" zu handeln, durchsuchen Sie die 2 verfügbaren Ergebnisse auf dieser Seite. Jedes Ergebnis zeigt einen aktuellen Preis, der die implizierte Wahrscheinlichkeit des Marktes darstellt. Um eine Position einzunehmen, wählen Sie das Ergebnis, das Sie für am wahrscheinlichsten halten, wählen Sie „Ja" um dafür oder „Nein" um dagegen zu handeln, geben Sie Ihren Betrag ein und klicken Sie auf „Handeln". Liegt Ihr gewähltes Ergebnis bei Marktauflösung richtig, zahlen Ihre „Ja"-Anteile jeweils $1 aus. Liegt es falsch, zahlen sie $0. Sie können Ihre Anteile auch jederzeit vor der Auflösung verkaufen.

Der aktuelle Favorit für „Wird Johnson & Johnson (JNJ) das Quartalsergebnis übertreffen?" ist „Wird Johnson & Johnson (JNJ) die Quartalsergebnisse übertreffen?" mit 87%, was bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 87% zuweist. Diese Quoten werden in Echtzeit aktualisiert, wenn Händler Anteile kaufen und verkaufen. Schauen Sie regelmäßig vorbei oder speichern Sie diese Seite als Lesezeichen.

Die Auflösungsregeln für „Wird Johnson & Johnson (JNJ) das Quartalsergebnis übertreffen?" definieren genau, was passieren muss, damit jedes Ergebnis als Gewinner erklärt wird – einschließlich der offiziellen Datenquellen zur Bestimmung des Ergebnisses. Sie können die vollständigen Auflösungskriterien im Abschnitt „Regeln" auf dieser Seite über den Kommentaren einsehen. Wir empfehlen, die Regeln vor dem Handeln sorgfältig zu lesen, da sie die genauen Bedingungen, Sonderfälle und Quellen festlegen.